Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Headache and Pain|August 5, 2020
Efficacy and safety of erenumab in women with a history of menstrual migraineJelena M Pavlovic, Koen Paemeleire, Hartmut Göbel, et al.
Cephalalgia : an International Journal of Headache|April 16, 2019
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled studyPeter J Goadsby, Koen Paemeleire, Gregor Broessner, et al.
Headache|October 31, 2018
Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ)Asha Hareendran, Anne Skalicky, Sally Mannix, et al.
The Journal of Headache and Pain|September 19, 2021
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trialKoichi Hirata, Fumihiko Sakai, Takao Takeshima, et al.
The Lancet. Neurology|September 16, 2008
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D Mikol, Frederik Barkhof, Peter Chang, et al.
Biochemical and Biophysical Research Communications|January 13, 2006
Neurofibromin binds to caveolin-1 and regulates ras, FAK, and AktMadanamohan Boyanapalli, Oscar B Lahoud, Ludwine Messiaen, et al.
Headache|June 7, 2019
Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ)Ariane K Kawata, Asha Hareendran, Shannon Shaffer, et al.
Headache|August 28, 2020
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% ResponseGregor Broessner, Uwe Reuter, Jo H Bonner, et al.
Cephalalgia : an International Journal of Headache|March 29, 2020
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension studyStewart J Tepper, Messoud Ashina, Uwe Reuter, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
Pageof 6